Intensity Therapeutics, Inc. (INTS) stock
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $10.71M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.40
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.04M
- EPS, diluted
- -$8.56
- Book value per share
- $2.35
- Diluted shares
- 3M
Trading
- Next earnings
- Mar 26, 2027 (estimated, during market hours)
- Previous close
- $3.09
- Open
- $3.16
- Day's range
- $3.16 – $3.39
- Volume
- 6,707
- Average volume (20 days)
- 14,007
- Beta (5 years)
- 0.58
- 52-week range
- $2.80 – $15.00
- RSI (14 days)
- 47.4
- Volatility (1 year)
- 84.6%
- Relative volume
- 0.27×
- WACC
- 7.8%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | INTS | S&P 500 | Difference | INTS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.6% | -2.4% | −7.2 pts | ||
| 3 months | -21.9% | -1.2% | −20.8 pts | ||
| Year to date | -68.0% | +12.3% | −80.3 pts | ||
| 1 year | -66.4% | +12.4% | −78.8 pts | ||
| 3 years | -95.2% | +78.8% | −174.0 pts | -63.6% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Intensity Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Results
About Intensity Therapeutics
Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing localized intratumoral cancer therapies designed to stimulate systemic anti-cancer immune activation. Utilizing its proprietary DfuseRx discovery platform, the company creates formulations combining generic anti-cancer cytotoxic agents, such as cisplatin and vinblastine sulfate, with amphiphilic molecules to facilitate drug penetration and dispersion throughout dense tumor microenvironments. Its core product candidate, INT230-6, targets various solid tumors, including soft tissue sarcoma and early-stage or triple-negative breast cancer, serving cancer patients with major unmet medical needs.
Company profile, executives and historyIntensity Therapeutics stock: common questions
What is Intensity Therapeutics's stock price?
INTS closed at $3.28 on Nov 11, 2026, up 6.15% on the day. Over the past 52 weeks it traded between $2.80 and $15.00.
What is Intensity Therapeutics's market cap?
Intensity Therapeutics was worth $10.71M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is INTS's P/E ratio?
Intensity Therapeutics lost money over fiscal 2025 (diluted EPS -$8.56), so it has no meaningful P/E ratio.
Does Intensity Therapeutics pay a dividend?
No. Intensity Therapeutics has not paid a cash dividend over the last twelve months.
When does Intensity Therapeutics report earnings next?
Intensity Therapeutics is expected to report Q4 FY2026 results on Mar 26, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has INTS stock performed over the past year?
Including dividends, INTS returned -66.4% over the past year, against +12.4% for the S&P 500.
How many INTS shares are sold short?
0M shares were sold short at the latest FINRA report, 2.42% of the float, or 7.2 days of average trading volume.
Who are Intensity Therapeutics's competitors?
Companies most similar to Intensity Therapeutics by business, industry and size include STRO, IBRX, IPHA, MOLN, CADL.
See a number that looks wrong?